marked decrease in the amount of Sm antigen present.
Surprisingly, similar quantitative analysis after treatment with defined amounts of trypsin leads to an apparent increase in the amount of Sm antigen present in a nuclear extract, but the evidence to date suggests that this effect merely represents a change in size of molecule(s) carrying the antigenic determinant(s).
We conclude that the identification of Sm antigen as an snRNA-containing nuclear particle is as yet unclear. If both antigens are indeed major components of this group of nuclear particles, then their extraction from nuclei and their solubility properties do not appear to follow those reported for snRNA (Raj et af., 1975; Zieve & Penman, 1976 Trypsin can be readily coupled to Sepharose and used for affinity chromatography in the isolation of trypsin inhibitors, which may be eluted by changing the ionic conditions of the buffer. Thus the binding of trypsin and inhibitor is a reversible process, the equilibrium being changed by reagents that compete for the specific binding sites on both trypsin and the inhibitor molecules.
We have compared the inhibition of trypsin in free solution and trypsin-Sepharose by protein inhibitors of trypsin and by active-site titrants, employing P-naphthylamidase (MacDonald et af., 1966) and caseinolytic activity (Steven & Al-Habib, 1979) as assay systems. In these experiments we preincubated 1 pg of trypsin or an equivalent volume (200pl) of trypsin-Sepharose-4B with incremental additions of potential inhibitors in a final volume of 3.0ml of 0.1 M-Tris/HCI buffer, pH8.0, at 4OoC for 10min before adding 40pl of substrate (32mg of a-N-benzoyl-DL-arginine /3-naphthylamide/ml of dimethyl sulphoxide) and incubating for 1 h at 4OOC. The product, /3-naphthylamine, was assayed fluorimetrically (MacDonald et al., 1966) . Alternatively we used the casein-fluram assay (Steven & Al-Habib, 1979) . The active-site titrants 4-nitrophenyl-4-guanidinobenzoate hydrochloride (Chase & Shaw, 1967) and 4-methylumbelliferyl-4-guanidinobenzoate hydrochloride (Coleman et al., 1976) inhibit trypsin in free solution by substitution: the proteins ovomucoid, soya-bean trypsin inhibitor and the seven inhibitors of trypsin present in human serum (Heimburger, 1974) inhibit free trypsin stoicheiometrically.
In our assay systems the trypsin concentration was 13 nM and we found that the molarities of the protein inhibitors required to totally inhibit this free trypsin were also of this order of magnitude, indicating stoicheiometry. On the other hand, 10-30 times higher concentrations were required to inhibit trypsinSepharose, e.g. 3 p~-4-nitrophenyl-4-guanidinobenzoate and -4-methylumbelliferyl-4-guanidinobenzoate caused 90% inhibition of trypsin-Sepharose (Fig. Id) , whereas one-tenth of this concentration caused similar inhibition of free trypsin; 1 5 0 n~ soya-bean trypsin inhibitor produced 60% inhibition (Fig. Ic) and 120nM ovomucoid produced 40% inhibition of trypsin-Sepharose (Fig. Ib) . We were unable to express the concentration of trypsin inhibitors in serum in molar terms, but 30pl of serum produced no detectable inhibition of trypsinSepharose ( Fig. la) , although 1 p1 of the same serum completely inhibited 1 pg of trypsin in free solution (Fig. le) . Concn. of active-site titrant ( p~) Fig. 1 . Inhibition of trypsin-Sepharose Inhibition of trypsin-Sepharose by incremental additions of (a) human serum ( b ) ovomucoid (c) soya-bean trypsin inhibitor assayed as P-naphthylamidase is shown. Trypsin-Sepharose inhibition by 4-nitrophenyl-4-guanidinobenzoate assayed with casein is shown in (d) compared with IOOnM required to inhibit 1 pg of trypsin in free solution. Inhibition of trypsin in free solution by serum (e), which typifies protein inhibitors of trypsin. assayed as P-naphthylamidase.
BIOCHEMICAL SOCIETY TRANSACTIONS
The data indicate that trypsin-Sepharose has markedly different inhibition kinetics from trypsin in free solution. The Sepharose granules (i) offer protection from inhibition in the first place (e.g. for active-site titrants; Fig. Id) and/or (ii) facilitate the displacement of inhibitor from trypsin by excess substrate (Figs. la, Ib and Ic). It would seem that when an inhibitor such as ovomucoid is preincubated with trypsin-Sepharose, all the enzyme molecules are initially complexed. On adding substrate, a certain proportion of trypsin-inhibitor complexes dissociate with regain of trypsin activity, this proportion being controlled by the relative concentrations of ovomucoid and substrate competing for enzyme active sites. As the relative concentration of inhibitor increases, greater inhibition results.
We conclude that surface-bound trypsin is far more effective enzymically than trypsin in free solution in the presence of inhibitors. Similar observations have been made on a trypsin-like neutral proteinase on tumour-cell surfaces (Steven et al., 1980) that may have significance for tumour invasion. In these experiments we employed the assay systems described in the preceding paper (Steven & Griffin, 1980) . In all experiments the cells were preincubated with incremental additions of potential inhibitor for IOmin before adding the substrate and starting the enzyme assay. The cells were originally surrounded by the ascitic fluid, which was shown to contain a potent inhibitor of trypsin in free solution but failed to inhibit the cell-surface trypsin-like neutral proteinase. Similarly, soya-bean trypsin inhibitor, ovomucoid, Trasylol and serum all failed to inhibit the tumour-cell-surface trypsin-Eke neutral proteinase when used in 20-fold excess of the concentrations required to inhibit an equivalent quantity of trypsin in free solution. Addition of I p g of trypsin in free solution to the test system containing cells, protein inhibitor of trypsin and substrate resulted in complete inhibition of the added trypsin in free solution, which showed that excess inhibitor was available in the test system and demonstrated that the added protein inhibitor was not sequestered by the cells and therefore unavailable for binding with the cell-surface trypsin-like neutral proteinase.
Low-molecular-weight inhibitors of trypsin in free solution were able to inhibit the cell-surface trypsin-Eke neutral proteinase. It was observed that 7-amino-1 -chloro-3-~-tosylamidoheptan-2-one ('TLCK') was almost equally effective as an inhibitor of trypsin in free solution, trypsin coupled with Sepharose 4B and the Ehrlich ascites-tumour cell trypsin-like neutral proteinase. Much higher concentrations of the active-site titrants for trypsin 4-nitrophenyl-4-guanidinobenzoate hydrochloride (Chase & Shaw, 1967) and 4-methylumbelliferyl-4-guanidinobenzoate (Coleman et a/., 1976) were required to inhibit the trypsin-like enzyme on the tumour cell surface compared with the concentration required to inhibit an equivalent quantity of trypsin in free solution (Fig. 1) . Similarly the active-site-directed agent 4-aminobenzamidine was required in higher concentrations to inhibit the tumour enzyme than to inhibit free trypsin (Fig. 1) .
The plots in Fig. 1 suggest that the tumour-cell surface provides an environment for the trypsin-like neutral prbteinase that is quite different from the aqueous environment surrounding trypsin in free solution. The net result of this cell-surface environment is that the trypsin-like neutral proteinase is either (i) not readily inhibited or (ii) readily dissociated from inhibitors when the substrate is added under conditions in which trypsin in free solution would remain totally inhibited. We were able to simulate this situation with trypsin-Sepharose (Steven & Griffin, 1980) , which encourages us to believe that this cellular proteolytic activity is truly trypsin-like and that the surface-bound enzymes will be virtually unaffected by the presence of high-molecular-weight inhibitors of trypsin in free solution, such as are known to be present in the ascitic fluid and serum (Heimburger, 1974) . 
